Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

<p>Supplementary Table S1: Genomic and clinical characteristics of the study cohort.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Ryan D. Chow (15109654) (author)
Andere auteurs:	Tai Michaels (15122331) (author), Stefania Bellone (15122334) (author), Tobias M.P. Hartwich (15122337) (author), Elena Bonazzoli (15122340) (author), Akiko Iwasaki (15122343) (author), Eric Song (15122346) (author), Alessandro D. Santin (15122349) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Therapeutic Research and Development Immuno-oncology Gynecological Cancers Endometrial cancer Immunotherapy Translational Research
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
door: Ryan D. Chow (15109654)
Gepubliceerd in: (2025)

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
door: Ryan D. Chow (15109654)
Gepubliceerd in: (2025)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
door: Ryan D. Chow (15109654)
Gepubliceerd in: (2025)

Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
door: Zannel Blanchard (16617018)
Gepubliceerd in: (2025)

Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
door: Zannel Blanchard (16617018)
Gepubliceerd in: (2025)

Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
door: Zannel Blanchard (16617018)
Gepubliceerd in: (2025)

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
door: Niccolò G. Santin (22229756)
Gepubliceerd in: (2025)

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
door: Niccolò G. Santin (22229756)
Gepubliceerd in: (2025)

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
door: Niccolò G. Santin (22229756)
Gepubliceerd in: (2025)

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
door: Niccolò G. Santin (22229756)
Gepubliceerd in: (2025)

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
door: Niccolò G. Santin (22229756)
Gepubliceerd in: (2025)

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
door: Niccolò G. Santin (22229756)
Gepubliceerd in: (2025)

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
door: Niccolò G. Santin (22229756)
Gepubliceerd in: (2025)

Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
door: Niccolò G. Santin (22229756)
Gepubliceerd in: (2025)

Table 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Table 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Image 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Table 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.docx
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Image 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Image 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Image 5_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.jpg
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Image 4_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Image 6_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Image 7_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tiff
door: Yumeng Cai (5591276)
Gepubliceerd in: (2025)

Table 1_Evaluation of microsatellite instability patterns in mismatch repair deficiency: a retrospective analysis of 285 endometrial cancers.docx
door: Cheng Wang (102692)
Gepubliceerd in: (2025)

Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
door: Shigehiro Yagishita (15088446)
Gepubliceerd in: (2025)

Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
door: Shigehiro Yagishita (15088446)
Gepubliceerd in: (2025)

Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
door: Shigehiro Yagishita (15088446)
Gepubliceerd in: (2025)

Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
door: Shigehiro Yagishita (15088446)
Gepubliceerd in: (2025)

Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
door: Arnaud Da Cruz Paula (17316230)
Gepubliceerd in: (2025)

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
door: Yi Tang (55726)
Gepubliceerd in: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
door: Martina S.J. McDermott (15206951)
Gepubliceerd in: (2025)